Bris­tol My­ers inks $11M deal to set­tle an­ti­com­pet­i­tive claims in HIV suit

Three years ago, AIDS ac­tivists filed a law­suit ac­cus­ing Bris­tol My­ers Squibb, Gilead, and John­son & John­son of schem­ing to block gener­ic HIV med­i­cines from the mar­ket, al­low­ing them to charge “ex­or­bi­tant, supra­com­pet­i­tive prices” for their own brand-name drug com­bi­na­tions.

Now BMS is will­ing to pay up to $11 mil­lion to put those claims in the rearview, while al­so open­ing the door for gener­ic com­pe­ti­tion to its fixed-dose reg­i­men Evotaz.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER